{"id":507449,"date":"2021-06-29T06:33:20","date_gmt":"2021-06-29T10:33:20","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/"},"modified":"2021-06-29T06:33:20","modified_gmt":"2021-06-29T10:33:20","slug":"medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/","title":{"rendered":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">LA JOLLA, Calif., June  29, 2021  (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and\u00a0Geoffrey O&#8217;Brien, JD\/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July\u00a013,\u00a02021 at\u00a04:30 pm\u00a0ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann.<\/p>\n<p align=\"justify\">\n        <strong><br \/>\n          <strong>About MediciNova<\/strong><br \/>\n        <\/strong>\n      <\/p>\n<p align=\"justify\">MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, MN-166 (ibudilast) and MN-001 (tipelukast), with multiple mechanisms of action and strong safety profiles, MediciNova has 11 programs in clinical development. MediciNova\u2019s lead asset, MN-166 (ibudilast), is currently in Phase 3 for amyotrophic lateral sclerosis (ALS) and degenerative cervical myelopathy (DCM), and is Phase 3-ready for progressive multiple sclerosis (MS). MN-166 (ibudilast) is also being evaluated in Phase 2 trials in glioblastoma, patients at risk of developing acute respiratory distress syndrome (ARDS), and substance dependence. MN-001 (tipelukast) is being evaluated in a Phase 2 trial in idiopathic pulmonary fibrosis (IPF) and is in preparation for a second Phase 2 trial in nonalcoholic steatohepatitis (NASH). MediciNova has a strong track record of securing investigator-sponsored clinical trials funded through government grants.<\/p>\n<p align=\"justify\">\n        <em>Statements in this press release that are not historical in nature constitute forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements include, without limitation, statements regarding the future development and efficacy of MN-166, MN-001, MN-221, and MN-029. These forward-looking statements may be preceded by, followed by or otherwise include the words &#8220;believes,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;intends,&#8221; &#8220;estimates,&#8221; &#8220;projects,&#8221; &#8220;can,&#8221; &#8220;could,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;would,&#8221; \u201cconsidering,\u201d \u201cplanning\u201d or similar expressions. These forward-looking statements involve a number of risks and uncertainties that may cause actual results or events to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause actual results or events to differ materially from those expressed or implied by these forward-looking statements include, but are not limited to, risks of obtaining future partner or grant funding for development of MN-166, MN-001, MN-221, and MN-029 and risks of raising sufficient capital when needed to fund MediciNova&#8217;s operations and contribution to clinical development, risks and uncertainties inherent in clinical trials, including the potential cost, expected timing and risks associated with clinical trials designed to meet FDA guidance and the viability of further development considering these factors, product development and commercialization risks, the uncertainty of whether the results of clinical trials will be predictive of results in later stages of product development, the risk of delays or failure to obtain or maintain regulatory approval, risks associated with the reliance on third parties to sponsor and fund clinical trials, risks regarding intellectual property rights in product candidates and the ability to defend and enforce such intellectual property rights, the risk of failure of the third parties upon whom MediciNova relies to conduct its clinical trials and manufacture its product candidates to perform as expected, the risk of increased cost and delays due to delays in the commencement, enrollment, completion or analysis of clinical trials or significant issues regarding the adequacy of clinical trial designs or the execution of clinical trials, and the timing of expected filings with the regulatory authorities, MediciNova&#8217;s collaborations with third parties, the availability of funds to complete product development plans and MediciNova&#8217;s ability to obtain third party funding for programs and raise sufficient capital when needed, and the other risks and uncertainties described in MediciNova&#8217;s filings with the Securities and Exchange Commission, including its annual report on Form 10-K for the year ended December 31, 2020 and its subsequent periodic reports on Form 10-Q and current reports on Form 8-K. Undue reliance should not be placed on these forward-looking statements, which speak only as of the date hereof. MediciNova disclaims any intent or obligation to revise or update these forward-looking statements.<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:40%;border-collapse:collapse\">\n<tr>\n<td colspan=\"2\">INVESTOR CONTACT:<\/td>\n<\/tr>\n<tr>\n<td style=\"max-width:4%;width:4%;min-width:4%\">\u00a0<\/td>\n<td style=\"max-width:96%;width:96%;min-width:96%\">Geoff O&#8217;Brien<br \/>Vice President<br \/>MediciNova, Inc.<br \/><a href=\"mailto:info@medicinova.com\" rel=\"nofollow noopener\" target=\"_blank\">info@medicinova.com<\/a><\/td>\n<\/tr>\n<\/table>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/da2ff626-ac20-4b55-9ad3-33cfb3afb376\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and\u00a0Geoffrey O&#8217;Brien, JD\/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July\u00a013,\u00a02021 at\u00a04:30 pm\u00a0ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-507449","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and\u00a0Geoffrey O&#8217;Brien, JD\/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July\u00a013,\u00a02021 at\u00a04:30 pm\u00a0ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, &hellip; Continue reading &quot;MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-06-29T10:33:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference\",\"datePublished\":\"2021-06-29T10:33:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/\"},\"wordCount\":699,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/\",\"name\":\"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\",\"datePublished\":\"2021-06-29T10:33:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/","og_locale":"en_US","og_type":"article","og_title":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk","og_description":"LA JOLLA, Calif., June 29, 2021 (GLOBE NEWSWIRE) &#8212; MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that Yuichi Iwaki, MD, PhD, President and Chief Executive Officer, and\u00a0Geoffrey O&#8217;Brien, JD\/MBA, Vice President and Executive Officer, will present a corporate overview at the Ladenburg Thalmann 2021 Virtual Healthcare Conference on Tuesday, July\u00a013,\u00a02021 at\u00a04:30 pm\u00a0ET. MediciNova will be available for one-on-one meetings at this conference and investors may request a one-on-one meeting through Ladenburg Thalmann. About MediciNova MediciNova, Inc. is a clinical-stage biopharmaceutical company developing a broad late-stage pipeline of novel small molecule therapies for inflammatory, fibrotic, and neurodegenerative diseases. Based on two compounds, &hellip; Continue reading \"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-06-29T10:33:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference","datePublished":"2021-06-29T10:33:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/"},"wordCount":699,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/","name":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=","datePublished":"2021-06-29T10:33:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODI3MTY2MyM0MjcyNjkyIzIwMDg1MTM="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/medicinova-to-present-at-the-ladenburg-thalmann-2021-virtual-healthcare-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"MediciNova to Present at the Ladenburg Thalmann 2021 Virtual Healthcare Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507449","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=507449"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/507449\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=507449"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=507449"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=507449"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}